Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.

@article{Lang2002TowardBE,
  title={Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.},
  author={Frederick F. Lang and Mark R. Gilbert and Vinay K. Puduvalli and Jeffrey T Weinberg and V. A. Levin and W. K. Alfred Yung and Raymond A Sawaya and Gregory N Fuller and Charles A. Conrad},
  journal={Neuro-oncology},
  year={2002},
  volume={4 4},
  pages={268-77}
}
Although no optimal treatment is currently available for malignant brain tumors, as the molecular mechanisms underlying brain tumor development have been delineated, new chemotherapeutic agents that act directly on specific molecular targets have become available. Defining a specific molecular target raises the possibility that the molecular effects of a given agent can be analyzed in patients in a clinical trial. Specifically, whereas standard phase I and II clinical trials classically… CONTINUE READING